+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Laboratory and clinical studies on amikacin

Laboratory and clinical studies on amikacin

Chinese Medical Journal 98(11): 807-816

Amikacin and other aminoglycoside antibiotics were tested for in vitro antibacterial activity against 480 strains of common pathogens, including Staphylococcus aureus. Escherichia coli, Shigella, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter, Proteus etc. The results indicated that home made amikacin was equal in potency to the Japanese made product. The in vitro antibacterial activity of amikacin was markedly superior to that of kanamycin, gentamycin, tobramycin, and streptomycin. Amikacin was active against organisms resistant to gentamicin, tobramycin and kanamycin. Clinical pharmacological studies were performed on 12 cases with normal renal functions. The peak level was 24.75 .mu.g/ml one hour after intramuscular injection of 400 mg amikacin. The biological half life was 2.39-2.48 hours. Thirty-one cases of infections caused by Gram negative rods and S. aureus were treated. 87.1% were considered effective. Renal and oto-toxicity was minimal. It is concluded that amikacin is a broad-spectrum, high potency aminoglycoside antibiotic, and is especially suitable for the treatment of severe Gram negative infections and those infections that were caused by gentamicin-tobramycin resistant Gram negative rods.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 005787335

Download citation: RISBibTeXText

PMID: 3938711

Related references

Laboratory and clinical studies on amikacin (BB-K8). Japanese Journal of Antibiotics 27(3): 348-353, 1974

Amikacin clinical and laboratory studies. Henry Ford Hospital Medical Journal 23(2): 57-64, 1975

Laboratory and clinical studies on amikacin (BB-K8), a new semisynthetic aminoglycoside. Japanese Journal of Antibiotics 27(3): 328-336, 1974

Clinical and laboratory studies with amikacin in newborns, infants, and children. Journal of Infectious Diseases 134 Suppl: S406-S411, 1976

Amikacin in obstetric, gynecologic, and neonatal infections: laboratory and clinical studies. Journal of Infectious Diseases 134 Suppl: S374-S379, 1976

Laboratory and clinical studies of amikacin intravenous drip infusion for the severe infections complicated with hematologic malignancies. Japanese Journal of Antibiotics 34(6): 832-840, 1981

Laboratory and clinical studies on imipenem/cilastatin sodium plus amikacin sulfate in patients with severe infections complicating hematological disorders. Japanese Journal of Antibiotics 44(5): 515-528, 1991

Laboratory and clinical evaluation of amikacin (BB-K8). Japanese Journal of Antibiotics 27(5): 620-624, 1974

Clinical and laboratory evaluation of amikacin. Polski Tygodnik Lekarski 34(44): 1721-1725, 1979

Laboratory and clinical investigation of amikacin (BB-K8). Japanese Journal of Antibiotics 27(3): 343-347, 1974

Clinical and laboratory evaluation of amikacin bb k8 in children. Abstracts of the Annual Meeting of the American Society for Microbiology 75:, 1975

Laboratory and clinical investigation on amikacin (BB-K8) in complicated infections of the urological field. Japanese Journal of Antibiotics 27(2): 226-233, 1974

Resistance to antibiotic synergism in Streptococcus faecalis: further studies with amikacin and with a new amikacin derivative, 4'-deoxy, 6'-N-methylamikacin. Antimicrobial Agents and ChemoTherapy 19(4): 549-555, 1981

Clinical laboratory approach to evaluate efficacy of amikacin. Reevaluation of in vitro MIC break points in disc susceptibility test. Japanese Journal of Antibiotics 45(5): 489-501, 1992

A randomized clinical trial of ceftazidime and amikacin versus ceftriaxone and amikacin in febrile patients with hematological neoplasia and severe neutropenia. British Journal of Haematology 93(SUPPL 2): 267, 1996